A detailed history of Tower Research Capital LLC (Trc) transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,665 shares of ADAP stock, worth $2,752. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,665
Holding current value
$2,752
% of portfolio
0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.92 - $1.39 $4,291 - $6,484
4,665 New
4,665 $4,000
Q4 2023

Feb 13, 2024

BUY
$0.43 - $0.79 $1,129 - $2,075
2,627 Added 32.69%
10,664 $8,000
Q3 2023

Nov 14, 2023

SELL
$0.73 - $1.04 $5,867 - $8,358
-8,037 Reduced 50.0%
8,037 $6,000
Q2 2023

Aug 14, 2023

BUY
$0.9 - $1.51 $3,421 - $5,741
3,802 Added 30.98%
16,074 $14,000
Q1 2023

May 09, 2023

BUY
$1.06 - $2.16 $4,541 - $9,253
4,284 Added 53.63%
12,272 $13,000
Q4 2022

Feb 10, 2023

SELL
$1.05 - $2.53 $22,976 - $55,361
-21,882 Reduced 73.26%
7,988 $12,000
Q3 2022

Nov 10, 2022

BUY
$1.06 - $2.41 $515 - $1,171
486 Added 1.65%
29,870 $32,000
Q2 2022

Aug 15, 2022

BUY
$1.33 - $2.28 $32,812 - $56,249
24,671 Added 523.47%
29,384 $50,000
Q1 2022

May 12, 2022

SELL
$1.73 - $4.06 $2,101 - $4,932
-1,215 Reduced 20.5%
4,713 $10,000
Q4 2021

Feb 14, 2022

SELL
$3.5 - $5.68 $11,028 - $17,897
-3,151 Reduced 34.71%
5,928 $22,000
Q3 2021

Nov 15, 2021

BUY
$3.44 - $6.37 $16,646 - $30,824
4,839 Added 114.13%
9,079 $47,000
Q2 2021

Aug 16, 2021

SELL
$3.86 - $5.78 $5,539 - $8,294
-1,435 Reduced 25.29%
4,240 $18,000
Q1 2021

May 17, 2021

BUY
$4.9 - $6.83 $14,660 - $20,435
2,992 Added 111.52%
5,675 $30,000
Q4 2020

Feb 16, 2021

BUY
$4.0 - $9.2 $10,732 - $24,683
2,683 New
2,683 $14,000
Q2 2020

Aug 13, 2020

SELL
$2.58 - $12.1 $24,744 - $116,051
-9,591 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.2 - $4.52 $11,314 - $42,619
9,429 Added 5820.37%
9,591 $26,000
Q4 2019

Feb 07, 2020

SELL
$0.72 - $1.43 $15,343 - $30,473
-21,310 Reduced 99.25%
162 $0
Q3 2019

Nov 05, 2019

BUY
$1.43 - $3.81 $30,561 - $81,427
21,372 Added 21372.0%
21,472 $32,000
Q2 2019

Aug 13, 2019

SELL
$3.23 - $5.41 $20,316 - $34,028
-6,290 Reduced 98.44%
100 $0
Q1 2019

May 14, 2019

BUY
$3.63 - $6.06 $23,195 - $38,723
6,390 New
6,390 $27,000
Q4 2018

Feb 14, 2019

SELL
$3.76 - $14.16 $1,864 - $7,023
-496 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$8.27 - $13.56 $12,115 - $19,865
-1,465 Reduced 74.71%
496 $7,000
Q2 2018

Aug 15, 2018

SELL
$10.42 - $13.74 $14,171 - $18,686
-1,360 Reduced 40.95%
1,961 $23,000
Q1 2018

May 15, 2018

SELL
$7.1 - $11.56 $10,657 - $17,351
-1,501 Reduced 31.13%
3,321 $37,000
Q4 2017

Feb 09, 2018

BUY
$6.68 - $8.74 $32,210 - $42,144
4,822
4,822 $32,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $96.4M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.